About VERIGRAFT
VERIGRAFT is a biotechnology company based in Gothenburg, Sweden. The company is rooted in the Karolinska Institute, based on groundbreaking basic science with a focus on regenerative medicine since 2014.
VERIGRAFT has grown to become a forerunner in industrialized tissue engineering and advanced regenerative medicine. The company has a strategically focused R&D pipeline of personalized tissues, targeting areas such as cardiovascular and neuronal disease. VERIGRAFT will commercialize a series of personalized tissue-engineered grafts on a global market. Current and future products will help millions of patients with today uncurable diseases, severely impacting quality of life and putting numerous patients out of work or into disability programs.
VERIGRAFT’s headquarters are located close to Gothenburg University and Sweden´s biggest university hospital in central Gothenburg. Here the company has state-of-the-art preclinical laboratories and offices. VERIGRAFT is led by a team of experienced scientists and entrepreneurs, and is backed by investors from Europe, Asia and the US.
“A paradigm shift in transplantation medicine”
VERIGRAFT offers a unique, breakthrough technology in the field of advanced regenerative medicine. The technology gives the opportunity to personalize tissues and organs. This will be able to bring a paradigm shift in transplantation medicine.
Petter Björquist
PhD, Chief Executive Officer
“Strong patents and solid IP-protection”
VERIGRAFTs unique technology is protected by world-wide patent families and trade secrets, giving the company a strong competitive advantage in the emerging field of regenerative medicine.
Raimund Strehl
PhD, Chief Technology Officer
“Enormous unmet medical need”
VERIGRAFT’s technology has the potential to increase the quality of life for millions of patients with severe diseases. Furthermore, it can generate enormous societal value by decreasing and shortening sick leaves. We believe VERIGRAFT is well positioned to provide products and services in this billion-dollar market.
Edvard Nordfors
Chief Financial Officer
Management
Petter Björquist
PhD, Chief Executive Officer
Petter holds a PhD in Biology/Biochemistry from Gothenburg University. Ten years within AstraZeneca R&D in Cardiovascular Diseases, twelve years at Cellartis/Cellectis as VP Regenerative Medicine, responsible for e.g., the major collaboration with Novo Nordisk on development of a human embryonic stem cell derived beta cell treatment for diabetes. CEO since 2014.
Raimund Strehl
PhD, Chief Technology Officer
Raimund holds a degree in cell biology from the University of Regensburg. Academic background within cell culture development and tissue engineering. Industrial background in the field of human pluripotent stem cell development and application. Over ten years at Cellartis, heading product development and manufacturingin and responsible for collaborations with major pharma and biotech companies. VERIGRAFTs CTO since 2015.
Edvard Nordfors
Chief Financial Officer
Edvard holds an MBA in Business Administration from the University of Gothenburg. Before joining VERIGRAFT in 2016, he had worked as CFO in both Sweden and the Netherlands. Edvard has extensive international experience in financial management, M&A and investments from both large and small companies across several industries, including the Life Science industry.
Board of Directors
Jan Holgersson
Chairman of the Board
Michelle Kim
Board member
KaHyoung Shin
Board member
Jonathan Finn
Board member
Dana Leach
Board member
Richard Warburg
Board member
Stefan-Erik von Euw
Board member